首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷核子醫學

市場調查報告書

商品編碼

1471986

Gallium-68 市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按應用程式、最終用戶和地理位置

Gallium-68 Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Application, End User, and Geography

出版日期: 2024年03月04日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格

簡介目錄

鎵68市場規模預計將從2022年的7.8236億美元成長到2030年的10.7034億美元；預計2022年至2030年複合年成長率為4.0%。

Gallium-68 市場的市場促進因素

先進的放射技術為診斷和核子醫學、放射治療和介入放射學開闢了新的視野。電離輻射在診斷和治療中的應用使全球數百萬患者受益。正子斷層掃描 (PET) 是臨床環境中常用的核子醫學放射學方式，因為它有助於準確檢測、定位和表徵疾病。根據世界衛生組織 (WHO) 統計，全球每年進行超過 36 億次放射診斷檢查、3,700 萬次核醫手術和 750 萬次放射治療。根據歐盟委員會的數據，歐洲每年使用放射性藥物和影像儀器進行約 1,000 萬次核子醫學手術，以診斷疾病並提供有針對性的治療。這些技術也被用於腫瘤學、免疫學、感染研究、胃腸病學、心臟病學、神經病學和精神病學。用於 PET/CT 的新型放射性藥物的開發和推出以及不同腫瘤分期方法的準確性不斷提高，促進了鎵 68 市場的成長。例如，新推出的前列腺成像放射性藥物如Ga-68 gozetotide有助於更精確的前列腺癌成像。

鎵68市場的限制

放射性藥物的半衰期取決於放射性同位素的半衰期和放射化學穩定性以及製劑中放射性核種雜質含量等多種因素。大多數放射性藥物製劑含有半衰期很短的放射性同位素。 Gallium-68 必須在製備後 68 分鐘內使用。無菌撤回第一劑後多劑量放射性藥物製劑的保存期限取決於微生物條件。保存期限較短的診斷放射性藥物通常在醫院放射性藥劑科在給患者服用之前製備。鎵68的半衰期為68分鐘，遠低於氟18（109.8分鐘）和锝99m（6小時）等其他放射性藥物的半衰期。因此，放射性藥物的短壽命成為長期程序的障礙，這是限制鎵68市場成長的主要因素。

Gallium-68 市場的機會

Gallium-68 已成為治療診斷領域不可或缺的一部分，該領域將診斷測試與標靶治療相結合。將鎵 68 與镥 177 等治療性放射性藥物結合使用，提供了一個有前途的個人化癌症治療和管理機會。鎵 68 作為診斷工具和治療劑的雙重作用與人們日益重視個人化和精確的癌症照護一致。因此，日益成長的治療診斷和精準醫學預計將為市場成長提供利潤豐厚的機會。

Gallium-68 市場：細分市場概述

腫瘤學領域在 2022 年佔據最大的 68 鎵市場佔有率，預計在預測期內複合年成長率最高。腫瘤領域的市場細分為前列腺癌、神經內分泌腫瘤等。

按最終用戶分類，市場分為醫院、診斷和成像中心等。到 2022 年，醫院細分市場將佔據最大的鎵 68 市場佔有率。

Gallium-68 市場：地理概況

據估計，2022 年至 2030 年亞太地區的複合年成長率最高。印度和中國等亞太國家擁有 68 鎵市場的巨大成長潛力。 2022年，北美佔據最大的68鎵市場。由於混合成像等技術的進步、用於診斷和治療的新型放射性藥物的引入以及基於示踪劑原理的分子成像技術的發展，美國核醫學取得了顯著的發展。先進的醫療基礎設施、前列腺癌發病率和患病率的上升以及主要參與者的產品創新進一步促進了北美 68 鎵市場的擴張。根據國際癌症研究機構 (IARC) 的數據，美國的癌症病例數預計將從 2020 年的 228 萬例增加到 2040 年的 312 萬例。，這有利於鎵68市場的進步。

在準備 68 鎵市場報告時提到的一些主要一手和二手來源包括世界銀行數據、國家醫療服務體系 (NHS)、FDA（食品和藥物管理局）、EMA（歐洲藥品管理局）和WHO（世界衛生組織）。

歐洲
- 德國
- 法國
- 義大利
- 西班牙
- 英國
- 歐洲其他地區
亞太
- 澳洲
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 中東和非洲其他地區
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地區

第 10 章：產業格局

併購
協議、合作、合資企業
新產品發布
擴張和其他策略發展

第 11 章：競爭格局

關鍵參與者的熱圖分析
公司定位與專注

第 12 章：鎵 68 市場 - 主要公司概況

Novartis AG
ITM Medical Isotopes GmbH
IRE-ELiT SA
Telix Pharmaceuticals (US) Inc
Eckert and Ziegler Radiopharma Gmbh
ARTMS Inc
IBA Radiopharma Solutions
Cardinal Health
Rosatom
Evergreen Theragnostics Inc

第 13 章：附錄

簡介目錄

Product Code: TIPRE00029992

The gallium-68 market size is expected to grow from US$ 782.36 million in 2022 to US$ 1,070.34 million by 2030; it is anticipated to record a CAGR of 4.0% from 2022 to 2030.

Market Drivers of the Gallium-68 Market

Advanced radiation technology has opened new horizons in diagnostic and nuclear medicine, radiotherapy, and interventional radiology. The application of ionizing radiation in diagnoses and treatments benefits millions of patients globally. Positron emission tomography (PET) is a commonly used nuclear medicine radiology modality in clinical settings, as it aids in the accurate detection, localization, and characterization of diseases. According to the World Health Organization (WHO), more than 3,600 million radiology-based diagnostic examinations, 37 million nuclear medicine procedures, and 7.5 million radiotherapy treatments are performed annually worldwide. As per the European Commission, ~10 million nuclear medicine procedures are performed with radiopharmaceuticals and imaging instruments every year in Europe to diagnose diseases and deliver targeted treatments. These techniques are also adopted in oncology, immunology, infection studies, gastroenterology, cardiology, neurology, and psychiatry. The development and introduction of new radiopharmaceuticals for PET/CT and the growing accuracy of different tumor staging methods contribute to the gallium-68 market growth. For instance, newly introduced prostate imaging radiopharmaceuticals such as Ga-68 gozetotide help in more precise prostate cancer imaging.

Restraint of the Gallium-68 Market

The half-life of radiopharmaceuticals depends on the half-life and radiochemical stability of radioisotopes and the radionuclide impurity content in the preparation, among other miscellaneous factors. Most radiopharmaceutical preparations contain radioisotopes with very short half-lives. Gallium-68 must be used within 68 minutes of preparation. The shelf-life of a multidose radiopharmaceutical preparation after aseptic withdrawal of the first dose depends on microbiological conditions. Diagnostic radiopharmaceuticals having short shelf lives are usually prepared in the hospital radiopharmacy departments just before the administration to patients. The half-life of gallium-68 is 68 minutes, which is considerably less than the half-life of other radiopharmaceuticals such as fluorine-18 (109.8 minutes) and technetium-99m (6 hours). Therefore, the short life of radiopharmaceuticals turns out to be a hindrance in long-term procedures, which is a major factor restraining the gallium-68 market growth.

Opportunities in the Gallium-68 Market

Gallium-68 has become integral to the field of theranostics, which combines diagnostic testing with targeted therapy. Using gallium-68 with therapeutic radiopharmaceuticals like lutetium-177 presents a promising personalized cancer treatment and management opportunity. This dual role of gallium-68 as both a diagnostic tool and a therapeutic agent aligns with the increasing emphasis on personalized and precise cancer care. Thus, the increasing theranostics and precision medicine are expected to provide lucrative opportunities for market growth.

Gallium-68 Market: Segmental Overview

The oncology segment held the largest gallium-68 market share in 2022 and is anticipated to register the highest CAGR during the forecast period. The market for the oncology segment is subsegmented into prostate cancer, neuroendocrine tumors, and others.

The market, by end user, is categorized into hospitals, diagnostic and imaging centers, and others. The hospitals segment held the largest gallium-68 market share in 2022. Further, the same segment is anticipated to register the highest CAGR during the forecast period.

Gallium-68 Market: Geographical Overview

Asia Pacific is estimated to register the highest CAGR during 2022-2030. Countries in the Asia Pacific, such as India and China, hold significant potential for the growth of the gallium-68s market. In 2022, North America held the largest gallium-68 market share. Nuclear medicine in the US has grown significantly owing to advancements in technologies such as hybrid imaging, the introduction of novel radiopharmaceuticals for diagnosis and treatment, and the development of molecular imaging techniques based on the tracer principle. Access to advanced healthcare infrastructure, the rising incidence and prevalence of prostate cancer, and product innovations by key players further contribute to the expansion of the gallium-68 market in North America. According to the International Agency for Research on Cancer (IARC), the number of cancer cases in the US is expected to increase from 2.28 million cases in 2020 to 3.12 million cases by 2040. Thus, the increasing cancer cases are expected to boost demand for nuclear imaging, which favors the gallium-68 market progress.

A few of the major primary and secondary sources referred to while preparing the report on the gallium-68 market are the World Bank Data, National Health Service (NHS), FDA (Food and Drug Administration), EMA (European Medicines Agency), and WHO (World Health Organization).

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Gallium-68 Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Gallium-68 Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Gallium-68 Market - Global Market Analysis

6.1 Gallium-68 - Global Market Overview
6.2 Gallium-68 - Global Market and Forecast to 2030

7. Gallium-68 Market - Revenue Analysis (USD Million) - By Application, 2020-2030

7.1 Overview
7.2 Oncology
- 7.2.1 Prostate Cancer
- 7.2.2 Neuroendocrine Tumors
- 7.2.3 Others
7.3 Cardiology
7.4 Neurology
7.5 Others

8. Gallium-68 Market - Revenue Analysis (USD Million) - By End-User, 2020-2030

8.1 Overview
8.2 Hospitals
8.3 Diagnostic and Imaging Centers
8.4 Others

9. Gallium-68 Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

9.1 North America
- 9.1.1 North America Gallium-68 Market Overview
- 9.1.2 North America Gallium-68 Market Revenue and Forecasts to 2030
- 9.1.3 North America Gallium-68 Market Revenue and Forecasts and Analysis - By Application
- 9.1.4 North America Gallium-68 Market Revenue and Forecasts and Analysis - By End-User
- 9.1.5 North America Gallium-68 Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Gallium-68 Market
    - 9.1.5.1.1 United States Gallium-68 Market, by Application
    - 9.1.5.1.2 United States Gallium-68 Market, by End-User
  - 9.1.5.2 Canada Gallium-68 Market
    - 9.1.5.2.1 Canada Gallium-68 Market, by Application
    - 9.1.5.2.2 Canada Gallium-68 Market, by End-User
  - 9.1.5.3 Mexico Gallium-68 Market
    - 9.1.5.3.1 Mexico Gallium-68 Market, by Application
    - 9.1.5.3.2 Mexico Gallium-68 Market, by End-User

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
- 9.4.4 Rest of Middle East and Africa
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Gallium-68 Market - Key Company Profiles

12.1 Novartis AG
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies